Evidence in support of the validity of the TNF brake hypothesis

Annals of the Rheumatic Diseases

Volumn 72, Issue 12, 2013, Pages

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DICKKOPF 1 PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; DISEASE COURSE; HUMAN; INFLAMMATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; PRIORITY JOURNAL; WNT SIGNALING PATHWAY;

ADULT ONSET STILL'S DISEASE; AMYLOIDOSIS; ANALGESICS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOGENESIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887465551     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204485     Document Type: Note

References (10)

1. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis (AS). Ann Rheum Dis Published Online First: 16 March 2013. doi:10.1136/annrheumdis-2012-202698.
2. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
3. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
4. Pedersen SJ, Chiowchanwisawakit P, Lambert RG, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 2011;38:1349-54.
5. Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007;9:207-15.
6. Maksymowych WP. What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther 2009;11:101-2.
7. Maksymowych WP. Advances in pathogenesis through animal models and imaging. Nature Rev Rheumatol 2013;9:72-4.
8. Maksymowych WP, Morency N, Conner-Spady B, et al. Suppession of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23-8.
9. Van Der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
10. Haroon N, Inman RD, Learch TJ, et al. The impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum Published Online. doi:10. 1002/art.38070